Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 9/20 | 0.48 |
| ▸ | CDK9 | P50750 | 5/20 | 0.48 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.48 |
| ▸ | CLK1 | P49759 | 1/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 3/20 | 0.46 |
| ▸ | MAP2 | P11137 | 1/20 | 0.44 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3617529 | 0.80 | JAK2 (0.59) | DYRK1AJAK2JAK3 | |
| SCHEMBL29523335 | 0.80 | JAK2 (0.59) | DYRK1AJAK2JAK3 | |
| SCHEMBL3609540 | 0.75 | JAK2 (0.62) | JAK2JAK1JAK3 | |
| SCHEMBL3604228 | 0.75 | HAVCR2 (0.44) | CDK9JAK2HAVCR2CHEK1JAK1 | |
| SCHEMBL15090916 | 0.73 | HAVCR2 (0.47) | JAK2HAVCR2KDM4EJAK1TYK2 | |
| SCHEMBL3607833 | 0.71 | JAK2 (0.59) | DYRK1AJAK2JAK3 | |
| SCHEMBL3619485 | 0.70 | JAK2 (0.52) | JAK2JAK3 | |
| SCHEMBL3614269 | 0.70 | JAK2 (0.71) | JAK2JAK3MAP4K4 | |
| SCHEMBL18138214 | 0.69 | DYRK1A (0.47) | DYRK1AJAK2JAK1JAK3 | |
| SCHEMBL3610876 | 0.68 | JAK2 (0.46) | JAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518964-B2 | Tricyclic compounds useful as inhibitors of kinases | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | claimed |
| EP-1954290-B1 | TRICYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES | MERCK SHARP & DOHME (US) | 2012-07-25 | — | — | EP | claimed |
| US-20100048551-A1 | Tricyclic Compounds Useful as Inhibitors of Kinases | MERCK SHARP & DOHME LLC | 2010-02-25 | — | — | US | claimed |
| US-8518964-B2 | Tricyclic compounds useful as inhibitors of kinases | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518964-B2 | Tricyclic compounds useful as inhibitors of kinases | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518964-B2 | Tricyclic compounds useful as inhibitors of kinases | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-1954290-B1 | TRICYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES | MERCK SHARP & DOHME (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-1954290-B1 | TRICYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES | MERCK SHARP & DOHME (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20100048551-A1 | Tricyclic Compounds Useful as Inhibitors of Kinases | MERCK SHARP & DOHME LLC | 2010-02-25 | — | — | US | disclosed |
| US-20100048551-A1 | Tricyclic Compounds Useful as Inhibitors of Kinases | MERCK SHARP & DOHME LLC | 2010-02-25 | — | — | US | disclosed |
| US-20100048551-A1 | Tricyclic Compounds Useful as Inhibitors of Kinases | MERCK SHARP & DOHME LLC | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048551-A1 | Tricyclic Compounds Useful as Inhibitors of Kinases | JAK2, JAK3, JAK1 | DYRK1A 370/4885CDK9 122/4885DYRK2 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.